RapidAI combats life-threatening vascular and neurovascular conditions, including Stroke, Aneurysm & Pulmonary Embolism, through advanced imaging and patient workflow technology, to improve clinical decision making and increase efficiency from home to hospital, ER to OR, based on over 5 million scans from 2000+ hospitals. RapidAI is where AI meets patient care.
RapidAI is creating a more streamlined approach to the patient journey by enabling program directors and physicians to see aggregated visuals that help them identify bottlenecks in patient care and make operational decisions to better support physicians and patient outcomes. Together, this has ultimately driven the company to pursue an end-to-end strategy, with goals to be the first in the space to ensure the entire patient journey (from being transported by EMS, until the patient’s data is pushed into their EMR) is covered. As healthcare systems are strained by physician shortages, increasing patient volumes and the fatigue of a global pandemic, RapidAI gives healthcare teams a level of transparency across a variety of factors that help make better decisions for patients and physicians. In the vein of health equity, RapidAI's mission is to create technology that levels the playing field between small, large, rural, and urban hospitals, when it comes to accessing cutting edge-treatment for life threatening conditions like stroke, PE, and aneurysm. RapidAI recognizes that many hospitals, regardless of size or sophistication, have a standard non-contrast scanner. With this in mind, the team is continuously finding new and innovative ways to adapt RapidAI’s advanced scanning software products to work alongside non-contrast scanners to drive value for physicians, and offer state-of-the-art services regardless of hospital infrastructure.
RapidAI’s data-validated products are pushing the healthcare industry on a path forward by taking a unique and multidimensional approach to treating life threatening diseases. Unlike others in the imaging and hospital workflow space, RapidAI’s solutions address not only the clinical aspects of care, but also the many other external factors that affect patient outcomes. When identifying and treating life-threatening diseases, time is of the essence. A patient’s likelihood of survival and recovery has always been based on that patient’s ability to be identified and triaged quickly and to get to a care facility that can treat and respond to their needs. COVID-19 has made this process all the more complicated as emergency rooms vacancies fluctuate with each COVID-19 surge. RapidAI’s solutions hope to take “luck” out of the equation by better streamlining care teams and coordination, and provide a platform for teams to clearly document the entire patient journey. RapidAI knows that health tech companies must work alongside doctors, health systems, and thought leaders in the industry to ensure the company deeply understands all challenges these stakeholders face, and create solutions to meaningfully address them. In order to do that, RapidAI has developed several partnerships with industry organizations, including the Brain Aneurysm Foundation and the Pulmonary Embolism Response Team (PERT) Consortium (a group of physicians that guides and influences PE care and research), as well as built a strong program for key opinion leaders in each of the specialties the company touches.
Several trials have been conducted proving patients with large vessel occlusions (LVOs) and favorable imaging characteristics can receive endovascular thrombectomy (EVT) treatment in the extended time window of 6 to 24 hours after stroke onset. These clinical trials used RapidAI software to select patients eligible for EVT treatment. These trials were conducted in high-income countries with access to state-of-the-art technologies and abundant resources, but with RapidAI, similar results can be achieved in countries with less. The Brazilian government conducted a trial to determine the safety, efficacy, and feasibility of EVT in Brazil's public health care system. Titled the RESILIENT trial, many hospitals used AI software to select eligible patients for EVT. A total of 300 patients were enrolled, including 79 who had undergone thrombectomy during an open-label roll-in period. The results indicated that patients who received EVT treatment in conjunction with standard medical care within 8 hours after the onset of stroke symptoms had better functional outcomes at 90 days than patients who received standard care alone. Additionally, the economic evaluation of the trial showed that the long-term benefits of EVT treatment offset the initial higher cost of EVT in the public health care system of Brazil— further strengthening the case for incorporating mechanical thrombectomy in the Brazilian public stroke centers.